Isoagglutinin reduction in intravenous immunoglobulin (IgPro10, Privigen) by specific immunoaffinity chromatography reduces its reporting rates of hemolytic reactions: an analysis of spontaneous adverse event reports

BACKGROUND: Hemolysis is an infrequent but recognized and potentially serious adverse effect of intravenous immunoglobulin (IVIG). Relatively elevated hemolysis reporting rates were seen with some IVIG products with high anti‐A/B isoagglutinin content, among which IgPro10 (Privigen, CSL Behring). Fo...

Descripción completa

Detalles Bibliográficos
Autores principales: Shebl, Amgad, Gabriel, Susie, Van Dinther, Kristy, Hubsch, Alphonse, Lawo, John‐Philip, Hoefferer, Liane, Welsh, Susan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2020
Materias:
Blood Components
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7383922/
https://www.ncbi.nlm.nih.gov/pubmed/32410287
http://dx.doi.org/10.1111/trf.15846

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7383922/
https://www.ncbi.nlm.nih.gov/pubmed/32410287
http://dx.doi.org/10.1111/trf.15846

Ejemplares similares